Research says that artificial intelligence can help detect breast cancer and reduce the workload of doctors.

[Global Network Reporter Zhang Yang] Artificial intelligence has been increasingly applied to people’s lives. In the medical field, many medical institutions have begun to try to use artificial intelligence technology to assist doctors in diagnosis. Recently, according to foreign media reports, many medical institutions around the world began to experiment with artificial intelligence technology to assist in the diagnosis of breast cancer.

According to the report, Hungary was one of the first countries to adopt relevant technologies. Since 2021, at least five hospitals have used artificial intelligence technology to assist the detection of breast cancer.

In a study published in 2022, the researchers recorded the number of times breast cancer was identified in 250,000 scans using artificial intelligence programs, and found that this was almost consistent with the level of human radiologists, and the scanning results could be read faster. The conclusion of this study is that if this technology is incorporated into doctors’ daily work, it can effectively reduce the workload of radiologists.

According to a doctor who used an artificial intelligence application, he was shocked by the effectiveness of the artificial intelligence program, because he submitted some difficult cases he encountered in his career to artificial intelligence for diagnosis, and the program correctly identified cancer symptoms every time.

With the enhancement of artificial intelligence technology, artificial intelligence can gradually complete more complex tasks, and many companies have been committed to combining artificial intelligence technology with medical care for many years. For example, YiduCore, a medical intelligent brain independently developed by medical science and technology enterprises in China, is the accumulation of core technologies for many years and a highly competitive medical intelligent infrastructure.

By virtue of YiduCore’s powerful data processing and AI algorithm capabilities, as well as its accumulated medical knowledge, insights and disease models, Yidu Technology assists customers such as medical institutions to manage authorized data efficiently and with high quality, making uncountable data computable, and at the same time, through continuous iteration of independent learning, continuously accumulating and strengthening the modeled knowledge map, promoting real breakthroughs in clinical diagnosis and treatment, and further providing value in public health, research, diagnosis and treatment and other scenarios.

Regarding the application of artificial intelligence technology in the diagnosis and treatment of breast cancer, Yidu Technology told reporters that in a phase III study on the treatment of HER2-positive breast cancer patients conducted by its Happy Life Technology (HLT) in cooperation with a well-known domestic pharmaceutical company, Happy Life Technology implemented digital recruitment through artificial intelligence technology, accelerated the positioning of target patients, found HER2-positive breast cancer patients more quickly and accurately, and completed the recruitment of patients with the target number.

Although artificial intelligence technology is rampant, many doctors or experts in artificial intelligence also said that artificial intelligence technology can not replace doctors, but is only used for auxiliary medical care. For example, when a doctor has made an assessment of the condition, he can use artificial intelligence to review it to prevent the occurrence of missed diagnosis.

Nature writes: In the next 30 years, cancer will cost the world 25 trillion US dollars.

Monoclonal antibody against B-cell psoriasis leukemia, a target of cancer artificial intelligence

①Nature:Cancer will cost the world $25 trillion over next 30 years

In the next 30 years, cancer may cost the world $25 trillion.

DOI :10.1038/d41586-023-00634-9

②Seminars in Cancer Biology:Artificial intelligence in cancer immunotherapy: applications in neoantigen recognition, antibody design and immunotherapy response prediction

Review: Application and development of artificial intelligence in the field of precision oncology: new antigen recognition, antibody design and immunotherapy response prediction.

DOI :10.1016/j.semcancer.2023.02.007

③Molecular Cancer:CD39/CD73/A2AR pathway and cancer immunotherapy

Review: New progress in pathophysiological function of CD39/CD73/A2AR pathway in cancer development, metastasis and drug resistance.

DOI :10.1186/s12943-023-01733-x

④Immunity:B cell receptor signaling in germinal centers prolongs survival and primes B cells for selection

B cell receptor signal transduction in germinal center prolongs the survival of B cells and initiates the selection of B cells.

DOI :10.1016/j.immuni.2023.02.003

⑤Frontiers in Immunology:Metabolic rewiring in keratinocytes by miR-31-5p identifies therapeutic intervention for psoriasis

The metabolic recombination of miR-31-5p in keratinocytes determines the intervention on psoriasis.

DOI :10.15252/emmm.202215674

⑥Journal of Hematology & Oncology:Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting

The latest drug research and new scheme progress of American Society of Hematology (ASH) for acute myeloid leukemia (AML)
DOI :10.1186/s13045-023-01411-x

⑦FDA extended the review of adult Roctavian with severe hemophilia A because of "significant changes in a large number of additional data"

⑧ A small molecule MET inhibitor, gumetinib, which was developed by Shanghai Institute of Pharmacology, China Academy of Sciences, was approved for marketing, and it was used for locally advanced or metastatic non-small cell lung cancer (NSCLC) with the jump mutation (METex14 jump) in exon 14 of mesenchymal-epithelial transforming factor (MET).

⑨ The clinical study of Relma-cel targeting CD19 for first-line high-risk large B-cell lymphoma was officially launched.

⑩ Lilly will terminate the research and development of Solanezumab for Alzheimer’s disease because it fails to slow down the cognitive decline of preclinical Alzheimer’s patients.

The world of scientific exploration is full of challenges. AtaGenix pays tribute to every pioneer and is more committed to becoming your trusted partner!

The beauty created by artificial intelligence AI is very realistic, don’t you think?

Really unbelievable, this turned out to be a beauty created by artificial intelligence AI. It’s amazing!

Really unbelievable, this turned out to be a beauty created by artificial intelligence AI, so beautiful!

Really unbelievable, this turned out to be a beauty created by artificial intelligence AI, so beautiful!

Really unbelievable, this turned out to be a beauty created by artificial intelligence AI, so realistic! ! !

It’s really unbelievable, it turned out to be a beauty created by artificial intelligence AI, so realistic! ! ! ! ! !

It’s really unbelievable, it turned out to be a beauty created by artificial intelligence AI, so realistic! ! ! ! ! !

It is said that a good-looking skin is the same, and a good-looking soul is one in a million. In fact, the beautiful skins are not necessarily the same, but may also be full of flowers and schools of thought contend!

In the Qing Dynasty, Zhao Yi once said: Talented people came out from the Jiangshan generation, each leading the way for hundreds of years.

This is actually very reasonable!

Just like the beauty created by these artificial intelligence AI, it is so realistic! ! ! ! ! ! Each has its own style!

What do you think?